好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Validating Patient Symptoms in the Electronic Health Record with Large Language Models for Scalable Tracking of Symptoms in Neuro-oncology
Palliative Care
P3 - Poster Session 3 (11:45 AM-12:45 PM)
11-004

To validate symptoms extracted from the electronic health record (EHR) with using large language modeling (LLM) to scale symptom extraction from the EHR.

Patients with brain tumors report high symptom burden, but there is little symptom research in this patient population. A methodology that scales symptom extraction from the EHR can facilitate better understanding of symptom pathophysiology and burden. Advances in LLMs may provide a means for scalable tracking of patient symptoms.

Our dataset comprised of 500 neuro-oncology clinical notes from 2020-2023, labeling the following symptoms: headache, fatigue, nausea, and anxiety. A physician labeled all clinical notes (gold standard) for whether the symptom was present or negated. The physician labeling was compared with a LLM, GPT-4o, assessing whether each symptoms was affirmed or negated. We ran the LLM using 1) the full clinical note and 2) a portioned section of the notes (interval history, assessment and plan). We calculated the performance of the LLM compared to the gold standard using standard metrics.

Across all symptoms, the average precision was 83.6%, average recall 91.6%, and average F1-score 86.9% (n=424). The LLM performed best with headache, resulting in 92.8% precision, 95.4% recall, and an F1-score of 94.1%, followed by nausea (94.4% precision, 85.0% recall, and an F1-score of 89.5%), fatigue (74.3% precision, 98.7% recall, and an F1-score of 84.8%), and anxiety (73.0% precision, 87.1% recall, and an F1-score of 79.4%). Running the LLM for the sectioned notes cost a third of the amount of full notes ($1.62 vs $5.03 for 500 notes).

LLMs performed very well for detecting headache, fatigue, nausea, and anxiety. LLMs offer the ability to scale symptom extraction from the chart, which is crucial for better understanding symptom burden and powering symptom-related interventions and studies. Sectioned notes are environmentally-friendly requiring less compute and costs.

Authors/Disclosures
John Y. Rhee, MD, MPH (Dana Farber Cancer Institute, Harvard Medical School)
PRESENTER
Dr. Rhee has stock in NTAP. Dr. Rhee has stock in TSLA. Dr. Rhee has stock in BABA. Dr. Rhee has stock in ZM. Dr. Rhee has stock in GM. Dr. Rhee has stock in PFF. Dr. Rhee has stock in AMZN. Dr. Rhee has stock in META. Dr. Rhee has stock in GE. The institution of Dr. Rhee has received research support from 好色先生. Dr. Rhee has received personal compensation in the range of $0-$499 for serving as a Director of the Hippocratic Forum with Hippocratic Society.
Thomas Sounack Mr. Sounack has nothing to disclose.
Zachary Tentor Mr. Tentor has nothing to disclose.
Joshua Davis Mr. Davis has nothing to disclose.
Brigitte Durieux Miss Durieux has nothing to disclose.
Paul Miller, Research Assistant Mr. Miller has received personal compensation for serving as an employee of Hillsdale College.
Rameen Beroukhim, MD, PhD An immediate family member of Dr. Beroukhim has received personal compensation for serving as an employee of Moderna. Dr. Beroukhim has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scorpion Therapeutics. Dr. Beroukhim has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Daiichi Sankyo. Dr. Beroukhim has stock in Takeda. Dr. Beroukhim has stock in Karyoverse Therapeutics. The institution of Dr. Beroukhim has received research support from Novartis. The institution of Dr. Beroukhim has received research support from NIH. Dr. Beroukhim has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Beroukhim has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with Ohio State University. Dr. Beroukhim has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with DKFZ.
Charlotta Lindvall, MD, PhD The institution of Dr. Lindvall has received research support from National Institutes of Health.